PDCD1 and non-small cell lung carcinoma: Another anti-PD-1 agent, pembrolizumab (KEYTRUDA, Merck & Co., Inc.)was approved for advanced melanoma in 2014, followed by several other approvals in other cancer types, such as advanced NSCLC in 2015, Hodgkin lymphoma and urothelial carcinoma in 2017.